Abstract

  Rilpivirine is an Anti-viral drug. Rilpivirine acts by inhibiting the replication of HIV – 1 by binding in a non – competitive manner directly to reverse transcriptase enzyme. In the present paper the authors have presented a review of various analytical methods published so far in the literature for the quantification of Rilpivirine in pharmaceutical preparations as well as biological samples.

Keywords: Rilpivirine; HIV; Anti-viral Drug

References

1. Garvey L and Winston A. “Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor”. Expert Opinion on Investigational Drugs7 (2009): 1035-1041.
2. Fernandez-Montero JV., et al. “Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection”. Expert Opinion on Pharmacotherapy7 (2012): 1007-1014.
3. Weiss J and Haefeli WE. “Potential of the novel antiretroviral drug Rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro”. International Journal of Antimicrobe Agents5 (2013): 484-487. 
4. Baert L., et al. “Development of a long-acting injectable formulation with nanoparticles of Rilpivirine (TMC278) for HIV treatment”. European Journal of Pharmaceutics and Biopharmaceutics72 (2009): 502-508.
5. Ramya B., et al. “Extractive spectrophotometric method for determination of non-nucleoside reverse transcriptase inhibitor in bulk and pharmaceutical dosage form”. IOSR Journal of Applied Chemistry11 (2017): 32-40.
6. Somsubhra Ghosh., et al. “Method development and validation of Rilpivirine in bulk and pharmaceutical tablet dosage form by using UV – Visible spectrophotometric method”. Asian Journal of Research Chemistry12 (2012): 1472-1475.
7. Vijaya Sri K., et al. “UV-visible spectrophotometric method for the estimation of Rilpivirine hydrochloride in pharmaceutical dosage form by using multivariate technique”. Chemical Science Transactions 3 (2015): 799-805.
8. Vijayalakshmi R., et al. “Application of first derivative spectrophotometric method for the determination of Rilpivirine in pure and tablet formulations”. Der Pharma Chemica 1 (2014): 404-406.
9. Masthanamma Sk and Alekhya G. “Development and validation of UV spectrophotometric methods for estimation of rilpivirine in bulk and pharmaceutical formulation”. International Journal of
   Pharmaceutical Sciences and Research. 2 (2014): 483-489.
10. Girija BB., et al. “Development and validation of UV spectrophotometric method for estimation of Rilpivirine hydrochloride in bulk and pharmaceutical formulations”. American Journal of Pharmtech Research1 (2013): 450-458.
11. Yasodha A., et al. “RP-HPLC method development and validation of Rilpivirine”. International Journal of Pharmacy and Analytical Research 1 (2017): 18-38.
12. Abhijit AD., et al. “Development and validation of a simple and isocratic reversed-phase HPLC method for the determination of Rilpivirine from tablets, nanoparticles and HeLa cell lysates”. Biomed Chromatography5 (2015): 709-715.
13. Somsubhra Ghosh., et al. “Method development and validation of Rilpivirine in bulk and tablet doses form by RP-HPLC method”. Research Journal of Pharmacy and Technology 3 (2013): 240-243.
14. Raj Kumar B and Subrahmanyam KV. “A Validated Stability-Indicating RP-HPLC method for the determination of Rilpivirine”. Journal of Global Trends in Pharmaceutical Sciences 3 (2014): 1822-1826.
15. Rubesh Kumar., et al. “RP-HPLC method development and validation of Rilpivirine pharmaceutical dosage form”. International Journal of Pharmacy and Analytical Research 3 (2019): 329-337.
16. Shibata M., et al. “Development and application of a simple LC-MS method for the determination of plasma Rilpivirine (TMC-278) concentrations”. Journal of Medical Investigation 1-2 (2013): 35-40. 
17. Raju AV and Appala Raju N. “Development and validation of a LC-MS/MS method for the determination of Rilpivirine in sprague dawley rat serum and its application to pharmacokinetic study”. Asian Journal of Biomedical and Pharmaceutical Sciences21 (2013): 23-29.
18. Gupta A., et al. “Reliable LC-MS/MS assay for the estimation of Rilpivirine in human plasma: Application to a bioequivalence study and incurred sample reanalysis”. Drug Testing and Analysis 4 (2015): 290-299.
19. , et al. “Liquid chromatography‐tandem mass spectrometric assay for the non‐nucleoside reverse transcriptase inhibitor Rilpivirine in human plasma”. Biomed Chromatography 27.2 (2013): 172-178.

Citation

Citation: Yenda Manishankar and Mukthinuthalapati Mathrusri Annapurna. “The Residency Advisory Committee: Steering Pharmacy Postgraduate Training". Acta Scientific Pharmaceutical Sciences 5.1 (2021): .

Copyright

Copyright: © 2021 Yenda Manishankar and Mukthinuthalapati Mathrusri Annapurna. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.